DERMACINRX FOLIPLUS D- folic acid, vitamin d3 capsule, liquid filled

DermacinRx FoliPlus D by

Drug Labeling and Warnings

DermacinRx FoliPlus D by is a Prescription medication manufactured, distributed, or labeled by PureTek Corporation. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

DESCRIPTION

FoliPlus D™ is an orally administered prescription folate product for the dietary management of patients with unique nutritional needs requiring increased folate levels and Vitamin D supplementation due to Vitamin D deficiency.

FoliPlus D™ should be administered under the supervision of a licensed medical practitioner.

Each softgel contains:

Folic Acid ..........................................................................1 mg

Vitamin D 3 (cholecalciferol) ......................................3333 IU

Each softgel contains the following inactive ingredients: polyethylene glycol, gelatin, glycerin, corn oil, yellow 10 (ci 47005), titanium dioxide.

INDICATIONS AND DOSAGE

FoliPlus D™ is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels and Vitamin D supplementation.

FoliPlus D can be taken by women of childbearing age, pregnant women, and lactating and nonlactating mothers.

CLINICAL PHARMACOLOGY

The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization. Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules.

There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.

CONTRAINDICATIONS

This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. FoliPlus D is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

WARNINGS AND PRECAUTIONS

KEEP OUT OF THE REACH OF CHILDREN.

Tell your doctor if you have: kidney problems, thyroid disease. This medication should be used as directed during pregnancy or while breast-feeding. Consult your doctor about the risks and benefits.

Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B 12 is deficient. Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

ADVERSE REACTIONS 

Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

You should call your doctor for medical advice about serious adverse events. To report adverse side effects or to obtain product information, contact PureTek Corporation, at 1-877-921-7873.

DOSAGE AND ADMINISTRATION

Take one softgel daily or as directed by a healthcare practitioner.

HOW SUPPLIED

FoliPlus D™ is supplied as oval, light yellow translucent softgels and dispensed in child-resistant bottles of 30 softgels (NDC: 59088-128-54*).

* This product is a prescription-folate with or without other dietary ingredients that – due to increased folate levels (AUG 2 1973 FR 20750), requires an Rx on the label because of increased risk associated with masking of B 12 deficiency (pernicious anemia). Based on our assessment of the risk of obscuring pernicious anemia, this product requires licensed medical supervision, an Rx status, and a National Drug
Code (NDC) or similarly-formatted product code, as required by pedigree reporting requirements and supply-chain control as well as in some cases, for insurance-reimbursement applications.

All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.

STORAGE

KEEP OUT OF THE REACH OF CHILDREN.

Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].
Protect from heat, light and moisture.

Tamper Evident: Do not use if seal is broken or missing

Manufactured in the USA by:
PureTek Corporation
San Fernando, CA 91340

For questions or information
call toll-free: 877-921-7873
Visit: dermacinrx.com

Rev. 37809 07/16

PACKAGE LABEL / PRINCIPAL DISPLAY PANEL

Bottle Label (30 Tablets)

INGREDIENTS AND APPEARANCE

DERMACINRX FOLIPLUS D 
folic acid, vitamin d3 capsule, liquid filled

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC: 59088-128
Route of Administration	ORAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
FOLIC ACID (UNII: 935E97BOY8) (FOLIC ACID - UNII:935E97BOY8)	FOLIC ACID	1 mg
VITAMIN D (UNII: 9VU1KI44GP) (CHOLECALCIFEROL - UNII:1C6V77QF41)	VITAMIN D	83.325 ug

Inactive Ingredients
Ingredient Name	Strength
POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
GELATIN (UNII: 2G86QN327L)
GLYCERIN (UNII: PDC6A3C0OX)
CORN OIL (UNII: 8470G57WFM)
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)

Product Characteristics
Color	yellow	Score	no score
Shape	OVAL	Size	4mm
Flavor		Imprint Code
Contains

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 59088-128-54	30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	07/15/2016

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		07/15/2016

Labeler - PureTek Corporation (785961046)